ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. - Wikidata - awgldk - TriplyDB

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

http://www.wikidata.org/entity/Q39500478

about

Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications What is the Need for Prostatic Biomarkers in Prostate Cancer Management?Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.SPINK1 protein expression and prostate cancer progression.Molecular pathways and targets in prostate cancer The ETS family of oncogenic transcription factors in solid tumours.MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays.ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy Expression of ERG protein in prostate cancer: variability and biological correlates.Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers Oncogenic activation of ERG: A predominant mechanism in prostate cancer.Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.RNA biomarkers to facilitate the identification of aggressive prostate cancer ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.Biomarkers in prostate cancer surveillance and screening: past, present, and future.Genetic variations of α -methylacyl-CoA racemase are associated with sporadic prostate cancer risk in ethnically homogenous Koreans.Biomarkers for prostate cancer: present challenges and future opportunities.Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.Stromal Androgen Receptor in Prostate Cancer Development and Progression Quality of Life and Sexual Health in the Aging of PCa Survivors.

P2860

Q24289356-E17E3E1D-5521-467D-84C5-6920ABC6EC99 Q26797063-C4B1CB82-25F0-4EDE-8083-FA60E99F1B33 Q26798425-9347ECB3-D192-42AF-AB2D-DED9172AC781 Q27010695-F4F2100E-7C0F-4053-A7BE-115A07D37849 Q28540624-1119900A-E1B4-4E68-B0F9-4D71965F7507 Q28546607-2B5DC624-476D-4B6C-9DF1-35B0E46D3252 Q33761801-41C526BC-191B-4B3C-8F5D-4E64FAFC7D6F Q33862890-A3CD682A-38AD-4DFC-A565-EEBBD202723D Q34036819-23227C3C-5A25-4F0A-A07B-FAA0A00BF3D4 Q34203149-DF47292C-C008-4251-A221-A65A42558F90 Q34365632-F7CF7B4F-0B29-485B-B0B4-9F2A3F0BB756 Q34555986-8B4C198A-8472-4E25-9A13-CCF14D96E167 Q34574636-A6D5C89B-4471-43CA-B30D-3C3D80E433A7 Q34652823-8ACF5131-03B6-4B45-AD34-FA4C3248A5D4 Q35535396-4C725CD3-62B5-4CBB-A11B-73D1A2ADCFF1 Q35585704-8EE65998-87D4-4717-8B7B-B4A441303C02 Q35608000-49395C79-0AA0-4D4E-9C10-5F8EAD3726F7 Q35631603-55DA99BF-A05A-41D6-9B3C-DD43242A2587 Q35648290-92FD89CC-E4D4-4D40-8EDA-962C8784DB84 Q35685920-DECD3BD0-74F1-4DF1-87B4-BF5F007A20DA Q35690915-D070D6D3-4A7D-4451-AAED-3885DAB1D8DE Q35706611-E5AE74CA-E147-4881-82D6-593724AF6AB2 Q35731092-F3AB77F3-C75E-4E06-96F9-CD79E1B0DDEB Q35828702-888336BA-17E7-4398-AA28-8D668CF2C95B Q36004694-29392974-1F9F-4DF1-BF20-D700C094F6E6 Q36035812-4F403559-6513-42AF-8D1D-C59F671B761D Q36105102-A85F75F1-18E1-4A39-A8E3-72E6C8B9EE9A Q36260364-C2026BAA-14A6-4882-8C89-919BF7438FC9 Q36374619-6086A757-D5AC-46BB-BA3B-0D2E76ED3983 Q36741911-4ABEAB39-013B-4381-B2E0-9209A17BA771 Q36848024-FE0ADD65-7B3D-4AAF-A988-3AD752979E28 Q36899790-D975CB53-BCEE-44F6-837D-120B52CDBFF4 Q37156611-9A949650-8685-4FC0-88D3-EF8FA623625D Q37285569-72ABD6A9-8394-4801-9078-65357E66AF85 Q37300931-385855A7-58D2-4FE8-AC57-5882AE781DCA Q37409113-DAA4D376-DA34-48C2-9727-ACE18347ED9D Q37474443-9E891E91-1303-43A0-9EC2-07A4574FEA83 Q37520447-43CCB68B-A495-4C9D-8D0E-F2AAB6663ECA Q37629551-3584D21D-9980-465F-84F2-04AF8EEE4457 Q37686901-8CC398FF-EA6A-4A5F-A018-31CA6C2F0B8E

P2860

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

http://www.wikidata.org/entity/Q39500478

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

ERG status is unrelated to PSA ...... sence of antihormonal therapy.

@en

ERG status is unrelated to PSA ...... sence of antihormonal therapy.

@nl

type

label

ERG status is unrelated to PSA ...... sence of antihormonal therapy.

@en

ERG status is unrelated to PSA ...... sence of antihormonal therapy.

@nl

prefLabel

ERG status is unrelated to PSA ...... sence of antihormonal therapy.

@en

ERG status is unrelated to PSA ...... sence of antihormonal therapy.

@nl

P1433

Q39500478-0C04A368-10DC-4B4C-B0FD-823B266ED74E

P1476

Q39500478-7F65157E-219C-4D3A-BB30-2F3A8E563EFF

P2093

Q39500478-038792D2-F5A6-4C67-BC14-4D575F0176FE

Q39500478-0D02C9D1-0CE7-4290-A9CE-56A1BE54BFCA

Q39500478-0D48CC76-31AC-46D6-A463-66CE3A038B93

Q39500478-0D7D7973-906A-4C25-9FC0-31EBC4BFD7A1

Q39500478-706ACA25-A2E3-4888-A666-47C679EE5313

Q39500478-79880260-D593-47BF-9FF7-5210E7DAF64D

Q39500478-7A39C65B-E8A7-4750-8AAD-5D8CB91FB274

Q39500478-9526ABE4-597B-4299-8519-B6C98AAD1910

Q39500478-9D2D06AB-CC9C-491D-BC5D-ACB73FAE111F

Q39500478-9EF0B181-4228-4529-AB5D-30449E4FFA2A

P304

Q39500478-2252E371-0786-4960-9692-0331FBA558F8

P31

Q39500478-63A8C4DB-845C-420F-9D2F-BA095F83767C

P356

Q39500478-397D6018-ACE7-4BDE-9B62-2391CC123087

P407

Q39500478-01CD2F1B-95FC-427A-BB23-76CABFB5F542

P433

Q39500478-2362F998-BA3A-471F-B4EE-CDC62DE91CE9

P478

Q39500478-85EACC3A-AA25-4B4C-B76E-A79640045E24

P50

Q39500478-387CAF44-4D39-476C-A418-CC9CFF8A4347

Q39500478-4A266926-AE2F-4441-8C96-420AEC1E3ECD

P577

Q39500478-F4EA3C3F-D040-4E51-835D-CEC12F4BB708

P5875

Q39500478-C9F81A87-5AA9-431E-8693-B8BCBAFC5014

P698

Q39500478-345D42F5-125C-4D5B-9948-BB2BECF93F72

P356

1078-0432.CCR-11-1251

P1433

Clinical Cancer Research

P1476

ERG status is unrelated to PSA ...... bsence of antihormonal therapy

@en

P2093

Alvin Y Liu

http://www.w3.org/2001/XMLSchema#string

Andreas M Luebke

http://www.w3.org/2001/XMLSchema#string

Antje Krohn

http://www.w3.org/2001/XMLSchema#string

Carsten Bokemeyer

http://www.w3.org/2001/XMLSchema#string

Guido Sauter

http://www.w3.org/2001/XMLSchema#string

Hartmut Schlüter

http://www.w3.org/2001/XMLSchema#string

Hüseyin Sirma

http://www.w3.org/2001/XMLSchema#string

Jan C Brase

http://www.w3.org/2001/XMLSchema#string

Julia Müller

http://www.w3.org/2001/XMLSchema#string

Klaus Pantel

http://www.w3.org/2001/XMLSchema#string

P304

5878-5888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-1251

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Tennstedt

P577

2011-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51523437

http://www.w3.org/2001/XMLSchema#string

P698

21791629

http://www.w3.org/2001/XMLSchema#string